Literature DB >> 24286228

5-HT2A receptor antagonists for the treatment of neuroleptic-induced akathisia: a systematic review and meta-analysis.

Zacharias G Laoutidis1, Christian Luckhaus1.   

Abstract

Akathisia is a common and distressing extrapyramidal side-effect, which usually results from the use of antipsychotic medication. Previous reviews and meta-analyses have demonstrated a lack of evidence for the effectiveness of treatment strategies, which are traditionally used against neuroleptic-induced akathisia (NIA), i.e. beta-blockers, anticholinergic agents and benzodiazepines. In the last fifteen years, randomized trials have studied the effect of drugs with antiserotonergic properties on NIA. We conducted a systematic review of randomized control trials and used meta-analytic methods to quantify the overall effect size. PubMed and the Cochrane libraries were searched for eligible trials. Six randomized controlled trials were found, five of which included a placebo control group and qualified for our meta-analysis. The overall effect size in the analysis is RR = 7.10 with 95% CI 3.08-16.40 (p < 0.0001). Our findings suggest that 5-HT(2A) antagonists are effective in the treatment of NIA.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24286228     DOI: 10.1017/S1461145713001417

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  6 in total

Review 1.  Brexpiprazole: so far so good.

Authors:  Saibal Das; Preeti Barnwal; Blessed Winston A; Somnath Mondal; Indranil Saha
Journal:  Ther Adv Psychopharmacol       Date:  2016-02

2.  Heavy Alcohol Drinking Associated Akathisia and Management with Quetiapine XR in Alcohol Dependent Patients.

Authors:  Zimple Kurlawala; Vatsalya Vatsalya
Journal:  J Addict       Date:  2016-10-25

3.  Efficacy of Brexpiprazole as Adjunctive Treatment in Major Depressive Disorder With Irritability: Post Hoc Analysis of 2 Pivotal Clinical Studies.

Authors:  Maurizio Fava; Emmanuelle Weiller; Peter Zhang; Catherine Weiss
Journal:  J Clin Psychopharmacol       Date:  2017-04       Impact factor: 3.153

4.  Gabapentin enacarbil for antipsychotic induced akathisia in schizophrenia patients: a pilot open-labeled study.

Authors:  Masahiro Takeshima; Hiroyasu Ishikawa; Takashi Kanbayashi; Tetsuo Shimizu
Journal:  Neuropsychiatr Dis Treat       Date:  2018-11-22       Impact factor: 2.570

5.  In Vitro and In Vivo Characterization of PCC0104005, a Novel Modulator of Serotonin-Dopamine Activity, as an Atypical Antipsychotic Drug.

Authors:  Yanan Xu; Xiaoyin Zhu; Hongbo Wang; Shanyue Sun; Xin Yue; Jingwei Tian
Journal:  Sci Rep       Date:  2018-05-02       Impact factor: 4.379

Review 6.  Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole.

Authors:  Tetsuro Kikuchi; Kenji Maeda; Mikio Suzuki; Tsuyoshi Hirose; Takashi Futamura; Robert D McQuade
Journal:  Neuropsychopharmacol Rep       Date:  2021-05-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.